2020 ASCO Virtual Annual Meeting

Findings from three trials show that trastuzumab deruxtecan, an antibody–drug conjugate, shows clinically meaningful activity in HER2-expressing metastatic colorectal cancer, metastatic non-small-cell lung cancer, and advanced gastric or gastresophageal junction adenocarcinoma. From the global DESTINY-CR01 phase 2 trial, Salvatore Siena (Niguarda Cancer Center, Milan, Italy) reported an objective response rate of 45·3% (24/53 patients, 95% CI...